Results 41 to 50 of about 3,929 (111)
Serum chitotriosidase and neopterin levels in patients with ankylosing spondylitis
Therapeutic Advances in Musculoskeletal Disease, 2019 Background: The aim of this study was to assess the serum chitotriosidase (ChT) and neopterin levels in patients with ankylosing spondylitis (AS) and to evaluate whether serum ChT and neopterin levels are related to disease activity.
Ferdi Yavuz +3 more
doaj +1 more source
Immunity, Inflammation and Disease, Volume 13, Issue 12, December 2025.ABSTRACT Background Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the axial skeleton causing pain, inflammation, and stiffness. Individuals with axSpA are at greater risk of developing cardiovascular disease, which can be counteracted by physical activity. High‐intensity interval training (HIIT) has been shown to
Åsa Andersson +4 more
wiley +1 more source
International Journal of Dermatology, Volume 64, Issue 11, Page 2038-2044, November 2025.ABSTRACT Background Bimekizumab, a monoclonal antibody targeting interleukin (IL)‐17A and IL‐17F, has shown efficacy in psoriatic arthritis (PsA) clinical trials, but real‐world data on its effectiveness are limited. This study aimed to evaluate its real‐world effectiveness in PsA patients treated in dermatologic settings.
Giacomo Caldarola +12 more
wiley +1 more source
Arthritis Care &Research, Volume 77, Issue 10, Page 1229-1239, October 2025.Objective The objective of this study was to determine a core set of measures for youth with juvenile spondyloarthritis and axial disease (axJSpA), using the juvenile arthritis working group Outcome Measures in Rheumatology framework. Methods This was a prospective multicenter study of youth with axJSpA.
Timothy G. Brandon +8 more
wiley +1 more source
Arthritis Research & Therapy, 2023 Background The objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement.
Xenofon Baraliakos +12 more
doaj +1 more source
JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases
ACR Open Rheumatology, Volume 7, Issue 10, October 2025.Objective Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome usually involves bones, joints, and skin. Due to a lack of known pathogenesis and clinical trials, there is no standard treatment of SAPHO syndrome. Because none of the current treatments have a high efficacy and the risk of relapse is high, new treatment options for ...
Patrick Fazeli +9 more
wiley +1 more source
Immunity, Inflammation and Disease, Volume 13, Issue 10, October 2025.ABSTRACT Background Ankylosing spondylitis (AS) is a chronic autoimmune inflammatory disorder predominantly involving the axial skeleton. Understanding the cytokine and chemokine signatures in AS is crucial for elucidating disease mechanisms and identifying potential diagnostic biomarkers.
Huan Li +10 more
wiley +1 more source
The Journal of Dermatology, Volume 52, Issue 10, Page 1527-1535, October 2025.ABSTRACT Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain ...
Yiyi Wang +11 more
wiley +1 more source
Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort
Arthritis Care &Research, Volume 77, Issue 8, Page 1007-1013, August 2025.Objective The aim of this study was to examine patient‐reported treatment goals among individuals with psoriatic arthritis. Methods Participants in the Psoriatic Arthritis Research Consortium completed standardized assessments, including patient‐reported outcome (PROs) instruments, between 2017 and 2020.
Astia Allenzara +8 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 480-488, August 2025.The objective of this modeling and simulation analysis was to determine an intravenous (IV) secukinumab dosing regimen with steady‐state exposure within the ranges of the approved subcutaneous (SC) regimens (300 and 150 mg every 4 weeks [q4w]) and to predict the efficacy and safety of this IV regimen for patients with psoriatic arthritis (PsA) or axial
Thomas Dumortier +9 more
wiley +1 more source